ArticleJournal of pharmacy & bioallied sciences2024
Clinical Outcomes and Stroke Recurrence in Moyamoya Disease Post-Revascularization: A Retrospective Analysis.
Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Delayed Recognition and Stroke-Predominant Presentation in Down Syndrome-Associated Moyamoya Syndrome.Stroke · 2026Article
- Chinese expert consensus on the treatment and diagnosis of moyamoya disease and moyamoya syndrome (2024).Stroke and vascular neurology · 2026Article
- Functional and Angiographic Outcomes Following Surgical Revascularization in Pediatric Moyamoya Disease: A Single-Centre Cohort Study from Central Asia.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to assess the clinical characteristics, treatment outcomes, and recurrence risks in moyamoya disease (MMD) patients, focusing on the impact of revascularization and antiplatelet therapy. Materials and Methods: Forty-six MMD patients were analyzed. Data on demographics, clinical characteristics, treatment outcomes, and recurrence rates of ischemic and hemorrhagic strokes were collected. The effectiveness of revascularization and the role of antiplatelet therapy in preventing recurrent strokes were statistically evaluated. Results: The mean age was 19.5 years. Right-side weakness (28.3%) and left-side weakness (21.7%) were common symptoms. Pre-revascularization, recurrent ischemic strokes affected 58.7% of patients; post-revascularization, the incidence dropped to 8.7%. However, a high recurrence rate (39.1%) persisted among those not undergoing surgery. Post-revascularization hemorrhagic strokes were rare (6.5%). Antiplatelet therapy significantly reduced ischemic stroke recurrence ( Conclusion: Early intervention and continuous antiplatelet therapy are crucial in managing MMD. Despite reduced ischemic stroke recurrence post-revascularization, functional outcomes often remained unimproved, indicating the need for optimized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.